Condition (MeSH)
Congenital Disorders of Glycosylation
ClinicalTrials.gov lists 9 trials for Congenital Disorders of Glycosylation or a narrower condition beneath it. National Human Genome Research Institute (NHGRI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Congenital Disorders of Glycosylation itself; the rest are tagged with a narrower condition beneath it.
When did Congenital Disorders of Glycosylation trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 3 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Congenital Disorders of Glycosylation trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Not applicable | 2 |
| Observational | 6 |
How many Congenital Disorders of Glycosylation trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 5 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Congenital Disorders of Glycosylation trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 1 |
Which publications cover Congenital Disorders of Glycosylation? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genetic counseling for congenital disorders of glycosylation (CDG). | Journal of genetic counseling | 2024 | Yes |
| Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2-CDG. | Human mutation | 2024 | Yes |
| NGLY1 deficiency: a prospective natural history study. | Human molecular genetics | 2023 | Yes |
| NGLY1 deficiency: estimated incidence, clinical features, and genotypic spectrum from the NGLY1 Registry. | Orphanet journal of rare diseases | 2022 | Yes |
| D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trial. | Orphanet journal of rare diseases | 2021 | Yes |
Showing 5 of 14 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital disorder of glycosylation | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Congenital disorder of glycosylation | Prevalence at birth | 1-9 / 100 000 | Europe | Not stated | Exact |
| Congenital disorder of glycosylation | Prevalence at birth | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Congenital disorder of glycosylation | Prevalence at birth | 1-9 / 100 000 | Europe | Not stated | Exact |
| Congenital disorder of glycosylation | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital disorder of glycosylation | 137 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Congenital disorder of glycosylation | 137 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.